|
[1]UMAR M, KHAN AG, ABBAS Z, et al.World Gastroenterology Organisation global guidelines:diagnosis, management and prevention of hepatitis C April 2013[J].J Clin Gastroenterol, 2014, 48 (3) :204-217.
|
|
[2]DUAN ZP, JIA JD, HOU J, et al.Current challenges and the management of chronic hepatitis C in mainland China[J].J Clin Gastroenterol, 2014, 48 (8) :679-686.
|
|
[3]Chinese Society of Hepatoloy and Chinese Society of Infection Dieases, Chines Medical Association.The guideline of prevention and treatment for hepatitis C:a 2015 update[J].J Clin Hepatol, 2015, 31 (12) :1961-1979. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.丙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1961-1979.
|
|
[4]LISTED N.Virus interference:I.The interferon.By Alick Isaacs and Jean Lindenman, 1957[J].CA Cancer J Clin, 1988, 38 (5) :280-290.
|
|
[5]DAVIS GL, BALART LA, SCHIFF ER, et al.Treatment of chronic hepatitis C with recombinant interferon alfa[J].N Engl J Med, 1990, 321 (22) :1501-1506.
|
|
[6]LEE SS, BAIN VG, PELTEKIAN K, et al.Treating chronic hepatitis C with pegylated interferon alfa-2a (40 KD) and ribavirin in clinical practice[J].Aliment Pharm Thera, 2006, 23 (3) :397-408.
|
|
[7]RAO H, WEI L, SHANG J, et al.Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection[J].J Gastroenterol Hepatol, 2014, 29 (3) :545-553.
|
|
[8]DAI CY, CHUANG WL, YU ML.Variants of the inosine triphosphate pyrophosphatase gene and relapse risk following treatment for HCV genotype 2/3[J].Hepatology, 2014, 60 (6) :2129-2130.
|
|
[9]AASLD/IDSA HCV Guidance Panel.Hepatitis C guidance:AASLDIDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus[J].Hepatology, 2015, 62 (3) :932-954.
|
|
[10]European Association for Study of Liver.EASL recommendations on treatment of hepatitis C 2016[EB/OL].[2017-1-20].http://www.easl.eu/medias/cpg/HCV2016/English-report.pdf.
|
|
[11]World Health Organization.Guidelines for the screen, care and treatment of persons with chronic hepatitis C infection[EB/OL].[2017-1-20].http://www.who.int.
|
|
[12]American Association for the study of Liver Disease and Infectious Diseass Society of America.HCV Guidance:recommendations for testing, managing, and treating hepatitis C[EB/OL].[2017-1-20].http://hcvguidelines.org/.
|
|
[13]SIEDERDISSEN CHZ, MAASOUMY B, MARRA F, et al.Drug-drug interactions with novel all oral interferon-free antiviral agents in a large real-world cohort[J].Clin Infect Dis, 2016, 62 (5) :561-567.
|
|
[14]FELD JJ, KOWDLEY KV, COAKLEY E et al.Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin[J].N Engl J Med, 2014, 370 (17) :1594-1603.
|
|
[15]LI JZ, CHAPMAN B, CHARLEBOIS P, et al.Comparison of illumina and 454 deep sequencing in participants failing raltegravirbased antiretroviral therapy[J].PLo S One, 2014, 9 (3) :e90485.
|
|
[16]CONTI F, BUONFIGLIOLI F, SCUTERI A, et al.Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals[J].J Hepatol, 2016, 65 (4) :727-733.
|
|
[17]van der MEER AJ, FELD JJ, HOFER H, et al.Risk of cirrhosisrelated complications in patients with advanced fibrosis following hepatitis C virus eradication[J].J Hepatol, 2016.[Epub ahead of print]
|
|
[18]AFDHAL N, ZEUZEM S, KWO P, et al.ION-1 Investigators.Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection[J].N Engl J Med, 2014, 370 (17) :1889-1898.
|
|
[19]AFDHAL N, REDDY KR, NELSON DR, et al.ION-2 Investigators.Ledipasvir and sofosbuvir for previously treated HCV genotype1 infection[J].N Engl J Med, 2014, 370 (17) :1483-1493.
|
|
[20]WEI L, HAN T, YANG D, et al.Simeprevir plus peginterferon/ribavirin for HCV genotype 1-infected treatment-na6ve patients in China and South Korea[J].J Gastroenterol Hepatol, 2016, 31 (5) :912-920.
|
DownLoad: